Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9394(65)95028-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-PD1 therapies induce an early expansion of Ki67CD8 T cells in metastatic non-oncogene addicted NSCLC patients.
Front Immunol
January 2025
Laboratory of Tumor Immunology and Cell Therapies, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. These therapies induced early modifications of the immune response impacting the clinical outcome. Identifying early changes in the immune system was critical to directing the therapeutic choice and improving the clinical outcome.
View Article and Find Full Text PDFThis review focuses on the latest advancements in using biomarkers to diagnose, predict outcomes, and guide the treatment of different types of thyroid cancer, such as anaplastic, papillary, medullary, and follicular thyroid carcinoma. We highlight the key role of both traditional and new biomarkers in improving the treatment of these cancers. For anaplastic thyroid cancer, biomarkers are crucial for detecting distant metastases and making treatment decisions.
View Article and Find Full Text PDFComprehensive analysis of genomic alterations and novel prognostic biomarkers, and establishment of prediction models of metastasis in metastatic non-small cell lung cancer.
J Cancer
January 2025
Department of Pulmonary and Critical Care Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Most patients with non-small cell lung cancer (NSCLC) have metastases at initial diagnosis. However, the comprehensive molecular characteristics and factors associated with its metastases are still needed. Tumor sequencing of 556 cancer-related genes was performed on 114 Chinese NSCLC patients.
View Article and Find Full Text PDFRandom survival forest predicts survival in patients with metastatic laryngeal and hypopharyngeal cancer and the prognostic benefits of surgery and radiotherapy.
J Cancer
January 2025
Department of Otolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Laryngeal and hypopharyngeal cancers are prominent within head and neck malignancies. The diagnosis of distant metastasis (DM) invariably signals poor prognosis, underscoring the need to optimize current treatment approaches. Patient data for metastatic laryngeal and hypopharyngeal cancer were extracted from the SEER database (2000-2020).
View Article and Find Full Text PDFUnclassifiable Renal Cell Carcinoma With an Estimated 100% Sarcomatoid Component: A Case Report.
Cureus
December 2024
Department of Anatomopathology, Mohammed VI University Hospital/Faculty of Medicine, Mohammed 1st University, Oujda, MAR.
Sarcomatoid renal cell carcinoma (RCC) is an aggressive tumour with a poor prognosis. It is not a distinct histological entity, as it can be found in any subtype of renal cell carcinoma. The majority of cases will present with advanced or metastatic disease requiring systemic treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!